These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 17520819)

  • 1. [Advances in the study of anti-atherosclerosis drugs].
    Guo CB; Li S
    Yao Xue Xue Bao; 2007 Mar; 42(3):231-5. PubMed ID: 17520819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New trends in lipidology: the increasing role of HDL-cholesterol].
    Paragh G; Harangi M; László M
    Orv Hetil; 2008 Jul; 149(30):1395-404. PubMed ID: 18621598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo.
    Naik SU; Wang X; Da Silva JS; Jaye M; Macphee CH; Reilly MP; Billheimer JT; Rothblat GH; Rader DJ
    Circulation; 2006 Jan; 113(1):90-7. PubMed ID: 16365197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDL-C as a new paradigm in atherosclerotic diseases.
    Shilpha S; Bairy KL
    Indian J Physiol Pharmacol; 2008; 52(4):319-26. PubMed ID: 19585750
    [No Abstract]   [Full Text] [Related]  

  • 5. Synthetic LXR agonists increase LDL in CETP species.
    Groot PH; Pearce NJ; Yates JW; Stocker C; Sauermelch C; Doe CP; Willette RN; Olzinski A; Peters T; d'Epagnier D; Morasco KO; Krawiec JA; Webb CL; Aravindhan K; Jucker B; Burgert M; Ma C; Marino JP; Collins JL; Macphee CH; Thompson SK; Jaye M
    J Lipid Res; 2005 Oct; 46(10):2182-91. PubMed ID: 16024916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinoid x receptor heterodimers in the metabolic syndrome.
    Shulman AI; Mangelsdorf DJ
    N Engl J Med; 2005 Aug; 353(6):604-15. PubMed ID: 16093469
    [No Abstract]   [Full Text] [Related]  

  • 7. HDL elevation and lipid lowering therapy: current scenario and future perspectives.
    Chhabria MT; Suhagia BN; Brahmkshatriya PS
    Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):214-27. PubMed ID: 18221121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The liver X receptor and atherosclerosis.
    Scott J
    N Engl J Med; 2007 Nov; 357(21):2195-7. PubMed ID: 18032771
    [No Abstract]   [Full Text] [Related]  

  • 9. LXR and PPAR activators stimulate cholesterol sulfotransferase type 2 isoform 1b in human keratinocytes.
    Jiang YJ; Kim P; Elias PM; Feingold KR
    J Lipid Res; 2005 Dec; 46(12):2657-66. PubMed ID: 16150827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The medicinal chemistry of liver X receptor (LXR) modulators.
    Tice CM; Noto PB; Fan KY; Zhuang L; Lala DS; Singh SB
    J Med Chem; 2014 Sep; 57(17):7182-205. PubMed ID: 24832115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combating atherosclerosis with LXR alpha and PPAR alpha agonists: is rational multitargeted polypharmacy the future of therapeutics in complex diseases?
    Kino T; Chrousos GP
    Mol Interv; 2004 Oct; 4(5):254-7. PubMed ID: 15471908
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment with LXR agonists after focal cerebral ischemia prevents brain damage.
    Sironi L; Mitro N; Cimino M; Gelosa P; Guerrini U; Tremoli E; Saez E
    FEBS Lett; 2008 Oct; 582(23-24):3396-400. PubMed ID: 18789330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid ligand-activated transcription factors regulating lipid storage and release in human macrophages.
    Chinetti-Gbaguidi G; Staels B
    Biochim Biophys Acta; 2009 Jun; 1791(6):486-93. PubMed ID: 19416654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of phenyl acetic acid substituted quinolines as novel liver X receptor agonists for the treatment of atherosclerosis.
    Hu B; Collini M; Unwalla R; Miller C; Singhaus R; Quinet E; Savio D; Halpern A; Basso M; Keith J; Clerin V; Chen L; Resmini C; Liu QY; Feingold I; Huselton C; Azam F; Farnegardh M; Enroth C; Bonn T; Goos-Nilsson A; Wilhelmsson A; Nambi P; Wrobel J
    J Med Chem; 2006 Oct; 49(21):6151-4. PubMed ID: 17034119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation by activating the liver X receptor.
    Lee JH; Gong H; Khadem S; Lu Y; Gao X; Li S; Zhang J; Xie W
    Endocrinology; 2008 Aug; 149(8):3778-88. PubMed ID: 18450964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPARs and other nuclear receptors in inflammation.
    Rizzo G; Fiorucci S
    Curr Opin Pharmacol; 2006 Aug; 6(4):421-7. PubMed ID: 16777482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis.
    Hansen MK; Connolly TM
    Curr Opin Investig Drugs; 2008 Mar; 9(3):247-55. PubMed ID: 18311660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptor agonists with phenethylphenylphthalimide skeleton derived from thalidomide-related liver X receptor antagonists: relationship between absolute configuration and subtype selectivity.
    Motoshima K; Ishikawa M; Hashimoto Y; Sugita K
    Bioorg Med Chem; 2011 May; 19(10):3156-72. PubMed ID: 21514830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluctuation of lipoprotein metabolism linked with bile acid-activated liver nuclear receptors in Alagille syndrome.
    Nagasaka H; Miida T; Hirano K; Ota A; Murayama K; Yorifuji T; Kobayashi K; Takatani T; Tsukahara H; Hui SP; Takayanagi M; Chiba H
    Atherosclerosis; 2008 Jun; 198(2):434-40. PubMed ID: 18430427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboxylic acid based quinolines as liver X receptor modulators that have LXRbeta receptor binding selectivity.
    Hu B; Quinet E; Unwalla R; Collini M; Jetter J; Dooley R; Andraka D; Nogle L; Savio D; Halpern A; Goos-Nilsson A; Wilhelmsson A; Nambi P; Wrobel J
    Bioorg Med Chem Lett; 2008 Jan; 18(1):54-9. PubMed ID: 18023179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.